



Attorney Docket No. 230  
**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re application of: **Munger et al.**

Serial No.: **08/900,752**

Group No.: **1205**

Filed: **July 25, 1997**

Examiner: **unassigned**

For: **NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD**

#6  
9/10  
5.11.98

**Assistant Commissioner for Patents**  
**Washington, D.C. 20231**

**INFORMATION DISCLOSURE STATEMENT (modified)**

**List of Sections Forming Part of This Information Disclosure Statement.**

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ FORM PTO - 1449 (Modified)
3. ☒ Copies of Listed Information Items Accompanying This Statement

**Section 1. Preliminary statements**

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

---

**CERTIFICATE OF MAILING**


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

**Robin Torres**

(Type or print name of person mailing paper)

Date: February 2, 1998

Robin Torres  
(Signature of person mailing paper)



IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97 (b).

Reg. No. 36,616

Daryl D. Muenchau  
SIGNATURE OF AGENT

Tel. No.: (650) 573-4712

Daryl D. Muenchau  
Type or print name of agent

Gilead Sciences, Inc.  
333 Lakeside Drive  
P.O. Address

Foster City, CA 94404

RECEIVED

FEB 17 1998

MANAGEMENT CENTER

2921

#6 1205  
1614



Attorney Docket No. 230  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

16C3

Re application of: Munger et al.

Serial No.: 08/900,752

Group No.: 1205

Filed: July 25, 1997

Examiner: unassigned

For: NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD

RECEIVED  
1614

FEB 17 1998

MATRIX OF  
SERVICE CENTER

Assistant Commissioner for Patents

Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN  
THREE MONTHS OF FILING OR BEFORE MAILING OF  
FIRST OFFICE ACTION (37 CFR 1.97 (b))

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

(check and complete appropriate item below);

37 CFR 1.8 (a)

☒ with sufficient postage as  
first class mail

or

37 CFR 1.10

☐ as "Express Mail Post  
Office to Addressee" Mailing  
Label  
No. \_\_\_\_\_

Robin Torres

(Type or print name of person mailing paper)

Date: February 2, 1998

Robin Torres  
(Signature of person mailing paper)

<b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <small>(37 CFR 1.98(b))</small>	ATTY Docket NO.: 230 <div style="position: absolute; top: -50px; left: 50px; border: 1px solid black; border-radius: 50%; padding: 5px; text-align: center;">           O I P E            FEB 05 1998            PATENT &amp; TRADEMARK OFFICE         </div>	SERIAL NO.: 08/900,752
	APPLICANT: Munger et al.	
	FILING DATE: 7/25/97	GROUP ART UNIT: 1205

**U.S. PATENT DOCUMENTS**

EXAMR'S INITIALS	PATENT NO.	ISSUE DATE	PATENTEE	CLASS/ SUBCLASS	FILING DATE
gao	5,663,159	9/2/97	Starrett, Jr. et al.	514/181	10/11/94

**FOREIGN PATENT DOCUMENTS**

EXAMR'S INITIALS	PATENT NO.	PUBLICATION DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES/NO
gao	0 481 214 A1	4/22/92	EUROPE	—	
gao	WO 95/07920	3/23/95	PCT	—	

**OTHER DOCUMENTS**

EXAMR'S INITIALS	ARTICLE
gao	De Clercq et al., "(S)-9-(2,3-dihydroxypropyl)adenine: An Aliphatic Nucleoside Analog with Broad-Spectrum Antiviral Activity", 200:563-565, SCIENCE, 1978
gao	Lindahl et al., "Synthesis of an Acyloxymethyl Prodrug of the Inositol Phosphate Alpha-Trinositol", 15(5):549-554, J CARBOHYDRATE CHEMISTRY, 1996
gao	Samara et al., "Pharmacokinetic Analysis of Diethylcarbonate Prodrugs of Ibuprofen and Naproxen", 16:201-210, Biopharmaceutics & Drug Disposition, 1995

EXAMINER	<i>James H. Cleaver</i>	DATE CONSIDERED	<i>11/23/98</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			